Story perspectives
FDA Fast-Tracks Two Innovative Gene Therapies for Rare Disorders
2/13/2025
38 8
1 of 1
Story summary
- The FDA has given a significant boost to Arbor Biotechnologies' ABO-101, a groundbreaking gene-editing therapy targeting primary hyperoxaluria type 1, with clinical trials set to kick off in early 2025. In a parallel advancement, Elixirgen's EXG-34217 for Telomere Biology Disorders has also secured RMAT designation, fast-tracking its Phase 1/2 trial for patients battling bone marrow failure.
